

Leishmaniasis

TURKEY

2014

Published in July 2016

Country General Information (WHO, 2013)

Total population:	74,933,000	Age group <15/>14 years, %:	26% / 74%
Gender (% F/M):	50.9% / 49.1%	Life expectancy at birth in years (F/M):	79 / 72
GDP (PPP int \$):	18 760	Number of 2nd sub-national administrative level divisions, name:	957, District
Income status:	Upper middle		



Epidemiology

	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Non endemic	Non endemic
Number of new cases (incidence):	22	3977	N/A	N/A
Number of relapse cases:	No data	No data	N/A	N/A
Total number of cases:	22	3977	N/A	N/A
Imported cases (n, %):	No data	2299 58%	No data	No data
Gender distribution (% F) ³ :	No data	53%	N/A	N/A
Age group distribution (% <5/5-14/>14) ^a :	(32/27/41)	(15/34/51)	N/A	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.03	0.50	N/A	N/A
Number of endemic 2nd sub-national administrative level divisions (n):	25	161	N/A	N/A
Population at risk ¹ (% n/total):	9% (6838486 /75932348)	44% (33419241 /75932348)	N/A	N/A
Was there any outbreak?	No	Yes	N/A	N/A
Number of new ² foci:	No data	No data	N/A	N/A



N/A = not applicable VL = visceral leishmaniasis CL = cutaneous leishmaniasis PKDL = post-kala-azar dermal leishmaniasis MCL = mucocutaneous leishmaniasis

Monthly distribution of new cases January-December

2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	1	3	0	4	1	1	6	2	2	1	0	1
CL	221	187	182	165	146	110	71	54	62	102	111	267



Incidence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014



¹ Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

² For this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever

³ Incidence rate at the national level


^a Age and gender distribution reported for autochthonous cases

^b In 2014 refers to autochthonous cases only

Distribution of new CL (left) and new (primary) VL (right) cases

Incidence of CL in Turkey in 2014 at district level per 10 000 population

Incidence of VL in Turkey in 2014 at district level per 10 000 population



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Map production: WHO/HTM/NTD/IDM

Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	1996	Year latest national guidelines were published:	2005
Type of surveillance:	Integrated	Is leishmaniasis a notifiable disease (mandatory reporting)?	Yes
Is there a vector control programme?	Yes	Is there a reservoir host control programme?	No
Type of insecticide used for IRS:	Alpha cypermethrine, cypermethrine, lambda cyhalothrin, imidacloprid	Number of leishmaniasis health facilities:	Leishmaniasis services integrated to primary health care facilities

Diagnosis

	VL	CL	PKDL	MCL
Number of people screened actively for:	9144	No data	N/A	N/A
Number of people screened passively for:	No data	No data	N/A	N/A
VL cases diagnosed by RDT* (% , RDT+/total VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT* (% , RDT+/total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , slides +/total cases):	100% (22/22)	100% (3977/3977)	N/A	N/A
Proportion of positive slides (% , slides +/total slides):	100% (22/22)	100% (3977/3977)	N/A	N/A
Cases diagnosed clinically (% , nb clinical cases/ total cases):	No data	100% (3977/3977)	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

* These indicators apply only for new (primary) VL cases.

VL = visceral leishmaniasis

PKDL = post-kala-azar dermal leishmaniasis

N/A = not applicable

CL = cutaneous leishmaniasis

MCL = mucocutaneous leishmaniasis

Treatment and medicines

Is treatment provided free of charge in the public sector?	Yes
Antileishmanial medicines included in the national List of Essential Medicines:	Meglumine antimoniate, sodium stibogluconate (SSG)

TREATMENT OUTCOME

	VL
Proportion of relapse cases: ⁴	No data
Initial cure rate:	No data
Failure ⁵ rate:	No data
Case-fatality rate:	No data

⁴ A relapse case in this country is defined as: No definition available

⁵ A failure case in this country is defined as: No definition available

Data source: Ministry of Health, Turkey
© WHO 2014. All rights reserved.